PedAM
Pediatric Disease Annotations & Medicines
| Disease | thromboembolism |
| Phenotype | C0026764|myeloma |
| Sentences | 12 |
| PubMedID- 23903204 | Melisse, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. |
| PubMedID- 19901114 | Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. |
| PubMedID- 25632017 | This study aims to determine the incidence of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory drug therapy in the ambulatory setting at uc health and to investigate adherence with guidelines developed by the national comprehensive cancer network for venous thromboembolism prevention in this patient population. |
| PubMedID- 24385802 | Aspirin and warfarin showed similar efficacy in reducing thromboembolic events in patients with myeloma treated with thalidomide-based regimens compared with lmwh, but in elderly patients warfarin showed less efficacy than lmwh [60]. |
| PubMedID- 20874693 | The background rate of thromboembolism is 4-11% in patients with multiple myeloma, which increases to 15-20% in patients who received intensive treatment with thalidomide. |
| PubMedID- 22511493 | We found multiple myeloma patients with venous thromboembolism to have a higher mortality at 1-, 5-, and 10-years of follow up compared with those without, with hazard ratios of 2.9 (95% confidence interval (ci) 2.4-3.5), 1.6 (95% ci: 1.5-1.8), and 1.6 (95% ci: 1.4-1.7), respectively. |
| PubMedID- 26432650 | This study focused on the clinical outcomes in multiple myeloma (mm) patients with venous thromboembolism (vte) who received low-molecular-weight heparin (dalteparin) therapy. |
| PubMedID- 26177588 | Lenalidomide treatment in combination with dexamethasone and/or chemotherapy is associated with a significant risk of venous thromboembolism (vte) in patients with multiple myeloma (mm). |
| PubMedID- 23014188 | Purpose of review: this review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (vte) in patients with lymphoma, multiple myeloma or acute leukemia. |
| PubMedID- 21859556 | Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. |
| PubMedID- 21282540 | In this randomized, open-label, multicenter trial, we compared aspirin (asa) or fixed low-dose warfarin (war) versus low molecular weight heparin (lmwh) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens. |
| PubMedID- 21255254 | Introduction: the incidence of venous thromboembolism (vte) in patients with multiple myeloma (mm) treated with thalidomide- and lenalidomide-based regimens is high. |
Page: 1